Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may present risk to patients treated with donor-derived microbiome therapies when appropriate manufacturing controls and inactivation processes are lacking. We report that the manufacturing steps for SER-109, a purified investigational mic...

Descripción completa

Detalles Bibliográficos
Autores principales: McChalicher, Christopher, Abdulaziz, Ahmad, Zhou, S Steve, Lombardo, Mary-Jane, Hasson, Brooke, Auniņš, John G, McGovern, Barbara H, Ege, David S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492665/
https://www.ncbi.nlm.nih.gov/pubmed/36158136
http://dx.doi.org/10.1093/ofid/ofac448
_version_ 1784793527578787840
author McChalicher, Christopher
Abdulaziz, Ahmad
Zhou, S Steve
Lombardo, Mary-Jane
Hasson, Brooke
Auniņš, John G
McGovern, Barbara H
Ege, David S
author_facet McChalicher, Christopher
Abdulaziz, Ahmad
Zhou, S Steve
Lombardo, Mary-Jane
Hasson, Brooke
Auniņš, John G
McGovern, Barbara H
Ege, David S
author_sort McChalicher, Christopher
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may present risk to patients treated with donor-derived microbiome therapies when appropriate manufacturing controls and inactivation processes are lacking. We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.
format Online
Article
Text
id pubmed-9492665
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94926652022-09-22 Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool McChalicher, Christopher Abdulaziz, Ahmad Zhou, S Steve Lombardo, Mary-Jane Hasson, Brooke Auniņš, John G McGovern, Barbara H Ege, David S Open Forum Infect Dis Brief Report Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may present risk to patients treated with donor-derived microbiome therapies when appropriate manufacturing controls and inactivation processes are lacking. We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2. Oxford University Press 2022-09-02 /pmc/articles/PMC9492665/ /pubmed/36158136 http://dx.doi.org/10.1093/ofid/ofac448 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
McChalicher, Christopher
Abdulaziz, Ahmad
Zhou, S Steve
Lombardo, Mary-Jane
Hasson, Brooke
Auniņš, John G
McGovern, Barbara H
Ege, David S
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
title Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
title_full Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
title_fullStr Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
title_full_unstemmed Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
title_short Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
title_sort manufacturing process of ser-109, a purified investigational microbiome therapeutic, reduces risk of coronavirus transmission from donor stool
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492665/
https://www.ncbi.nlm.nih.gov/pubmed/36158136
http://dx.doi.org/10.1093/ofid/ofac448
work_keys_str_mv AT mcchalicherchristopher manufacturingprocessofser109apurifiedinvestigationalmicrobiometherapeuticreducesriskofcoronavirustransmissionfromdonorstool
AT abdulazizahmad manufacturingprocessofser109apurifiedinvestigationalmicrobiometherapeuticreducesriskofcoronavirustransmissionfromdonorstool
AT zhoussteve manufacturingprocessofser109apurifiedinvestigationalmicrobiometherapeuticreducesriskofcoronavirustransmissionfromdonorstool
AT lombardomaryjane manufacturingprocessofser109apurifiedinvestigationalmicrobiometherapeuticreducesriskofcoronavirustransmissionfromdonorstool
AT hassonbrooke manufacturingprocessofser109apurifiedinvestigationalmicrobiometherapeuticreducesriskofcoronavirustransmissionfromdonorstool
AT auninsjohng manufacturingprocessofser109apurifiedinvestigationalmicrobiometherapeuticreducesriskofcoronavirustransmissionfromdonorstool
AT mcgovernbarbarah manufacturingprocessofser109apurifiedinvestigationalmicrobiometherapeuticreducesriskofcoronavirustransmissionfromdonorstool
AT egedavids manufacturingprocessofser109apurifiedinvestigationalmicrobiometherapeuticreducesriskofcoronavirustransmissionfromdonorstool

Ejemplares similares